Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.44 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.44 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.44 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 3/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634320 | 0.90 | MAOB (0.59) | MAOBFFAR1PDPK1PLAAT3PLAAT5 | |
| Trifluoroacetic Acid SCHEMBL4788988 | 0.87 | MAOB (0.53) | MAOBFFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL2316007 | 0.85 | TAAR1 (0.57) | MAOBFFAR1PDPK1PLAAT3PLAAT5 | |
| Cadaverine Tartrate SCHEMBL9937388 | 0.82 | MAP4K4 (0.47) | MAOBFFAR1PDPK1PLAAT3PLAAT5 | |
| Cadaverine Tartrate SCHEMBL9938552 | 0.81 | FFAR1 (0.45) | FFAR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| Cadaverine Tartrate SCHEMBL9938636 | 0.81 | ALDH1A1 (0.44) | FFAR1TAAR1RXRARXRBRXRG | |
| Cadaverine Tartrate SCHEMBL10560366 | 0.81 | TAAR1 (0.68) | MAOBFFAR1PDPK1PLAAT3PLAAT5 | |
| Cadaverine Tartrate SCHEMBL9936744 | 0.79 | ALDH1A1 (0.47) | FFAR1KIF11RXRARXRBRXRG | |
| SCHEMBL934147 | 0.77 | HDAC1 (0.57) | MAOBFFAR1PDPK1PLAAT3PLAAT5 | |
| Cadaverine Tartrate SCHEMBL3633167 | 0.77 | RARB (0.41) | FFAR1RXRARXRBRXRGPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080497-A2 | METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
| EP-2152865-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008140449-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-20 | — | — | WO | disclosed |